B. Pitt, F. Zannad, W. J. Remme, R. Cody, A. Castaigne et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, vol.341, pp.709-717, 1999.

B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez et al., Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, vol.348, pp.1309-1321, 2003.

F. Zannad, J. J. Mcmurray, H. Krum, D. J. Van-veldhuisen, K. Swedberg et al., Eplerenone in patients with systolic heart failure and mild symptoms, N Engl J Med, vol.364, pp.11-21, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01742988

J. L. Samuel and C. Delcayre, Heart failure: aldosterone antagonists are underused by clinicians, Nat Rev Cardiol, vol.7, pp.125-127, 2010.

J. Fagart, A. Hillisch, J. Huyet, L. Bärfacker, M. Fay et al., A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule, J Biol Chem, vol.285, pp.29932-29940, 2010.

D. Fraccarollo, S. Berger, P. Galuppo, S. Kneitz, L. Hein et al., Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction, Circulation, vol.123, pp.400-408, 2011.

A. Lother, S. Berger, R. Gilsbach, S. Rösner, A. Ecke et al., Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function, Hypertension, vol.57, pp.746-754, 2011.

A. Mccurley, P. W. Pires, S. B. Bender, M. Aronovitz, M. J. Zhao et al., Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors, Nat Med, vol.18, pp.1429-1433, 2012.

G. Galmiche, A. Pizard, A. Gueret, S. El-moghrabi, A. Ouvrard-pascaud et al., Smooth muscle cell mineralocorticoid receptors are mandatory for aldosteronesalt to induce vascular stiffness, Hypertension, vol.63, pp.520-526, 2014.

C. L. Sartório, D. Fraccarollo, P. Galuppo, M. Leutke, G. Ertl et al., Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction, Hypertension, vol.50, pp.919-925, 2007.

P. Mulder, V. Mellin, J. Favre, M. Vercauteren, R. Monteil et al., Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone, Eur Heart J, vol.29, pp.2171-2179, 2008.

L. Bärfacker, A. Kuhl, A. Hillisch, R. Grosser, S. Figueroa-pérez et al., Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases, ChemMedChem, vol.7, pp.1385-1403, 2012.

P. Kolkhof, M. Delbeck, A. Kretschmer, W. Steinke, E. Hartmann et al., Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury, J Cardiovasc Pharmacol, vol.64, pp.69-78, 2014.

L. Lu, M. T. Quinn, and Y. Sun, Oxidative stress in the infarcted heart: role of de novo angiotensin II production, Biochem Biophys Res Commun, vol.325, pp.943-951, 2004.

A. J. Rickard, J. Morgan, S. Chrissobolis, A. A. Miller, C. G. Sobey et al., Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure, Hypertension, vol.63, pp.1033-1040, 2014.

L. Calvier, M. Miana, P. Reboul, V. Cachofeiro, E. Martinez-martinez et al., Galectin-3 mediates aldosterone-induced vascular fibrosis, Arterioscler Thromb Vasc Biol, vol.33, pp.67-75, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00812594

M. L. Ambroisine, J. Favre, P. Oliviero, C. Rodriguez, J. Gao et al., Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-activated potassium (BKCa) channels of vascular smooth muscle cells, Circulation, vol.116, pp.2435-2443, 2007.

J. Xu, O. A. Carretero, C. X. Lin, M. A. Cavasin, E. G. Shesely et al., Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarction, Am J Physiol Heart Circ Physiol, vol.293, pp.1900-1907, 2007.

R. D. Patten, M. J. Aronovitz, M. Einstein, M. Lambert, N. G. Pandian et al., Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse, Clin Sci (Lond), vol.104, pp.109-118, 2003.

Y. Rautureau, P. Paradis, and E. L. Schiffrin, Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells, Steroids, vol.76, pp.834-839, 2011.

S. Johar, A. C. Cave, A. Narayanapanicker, D. J. Grieve, and A. M. Shah, Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase, FASEB J, vol.20, pp.1546-1548, 2006.

L. A. Martinez-lemus, T. Crow, M. J. Davis, and G. A. Meininger, alphavbeta3-and alpha5beta1-integrin blockade inhibits myogenic constriction of skeletal muscle resistance arterioles, Am J Physiol Heart Circ Physiol, vol.289, pp.322-329, 2005.

D. S. Marks, S. Gudapati, L. M. Prisant, B. Weir, C. Didonato-gonzalez et al., Mortality in patients with microvascular disease, J Clin Hypertens (Greenwich), vol.6, pp.304-309, 2004.

G. Montalescot, B. Pitt, E. Lopez-de-sa, C. W. Hamm, M. Flather et al., REMINDER Investigators; REMINDER Investigators. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study, Eur Heart J, vol.35, pp.2295-2302, 2014.

H. V. Joffe, R. Y. Kwong, M. D. Gerhard-herman, C. Rice, K. Feldman et al., Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus, J Clin Endocrinol Metab, vol.92, pp.2552-2558, 2007.